SB Names Surgipharm As Uganda Agent
SmithKline Beecham has appointed Surgipharm as its new agent in Uganda.According to its managing director, Kinny Nayr, Surgipharm will offer unique products not currently available in Uganda.
He added in an interview that SB "will, for the first time, produce medicines specifically for the Ugandan market, which will be made to the same exacting quality as its branded medicines, at competitive prices so that poor people will have the chance to have quality care at an economical price."
Surgipharm also plans to sell branded products which in most cases have no competitors or alternatives, and will also act as distributor for another UK drugmaker, Glaxo Wellcome.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze